Recent Updates
Recently added Catalysts
AGIO Positive Sentiment

Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET

Key Takeaway: Agios Pharmaceuticals will host a conference call and webcast on February 12, 2026, to discuss its fourth quarter and full year 2025 financial results. The event will be accessible via the company's website, with a replay available shortly after. Agios emphasizes its commitment to transforming rare disease treatment through innovative medicines.
Price reaction · baseline $28.54 (2026-01-23 close) · hit pre-market · 1 other AGIO headline(s) in the window, move may be shared
day 0 close · peak
+1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Agios is actively engaging with investors through a conference call.
  • The company is reporting its financial results, indicating transparency.
  • Agios is focused on innovative medicines for rare diseases.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+80%
120-day peak, hindsight
Typical move
5%
average across 13 past catalysts
Cash runway
~50 mo
Minimal dilution risk
Lead asset
Mitapivat
Phase 3 · Transfusion-dependent Alpha-Thalassemia

Full Press Release Details

CAMBRIDGE, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced the company will host a conference call and live webcast on Thursday, February 12, 2026, at 8:00 a.m. ET to report its fourth quarter and full year 2025 financial results and business highlights.
The live webcast will be accessible on the Investors section of the company’s website (www.agios.com) under the “Events & Presentations” tab. A replay of the webcast will be available on the company’s website approximately two hours after the event.
About Agios: Fueled by Connections to Transform Rare Diseases™At Agios, our vision is to redefine the future of rare disease treatment. Fueled by connections, we build trusted partnerships with communities – collaborating to develop and deliver innovative medicines that have the potential to transform lives. With a foundation in hematology, we combine biological expertise with real-world insights to advance a growing pipeline of rare disease medicines that reflect the priorities of the people we serve. Agios is a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. To learn more, visitwww.agios.comand follow us onLinkedInandX.

Contacts:Investor ContactMorgan Sanford, Vice President, Investor RelationsAgios Pharmaceuticalsmorgan.sanford@agios.com

Media ContactEamonn Nolan, Senior Director, Corporate CommunicationsAgios Pharmaceuticalseamonn.nolan@agios.com

Frequently Asked Questions

When will Agios host its financial results conference call?

Agios will host the call on February 12, 2026, at 8:00 a.m. ET.

How can I access the Agios conference call?

The conference call will be accessible on Agios' website under the 'Events & Presentations' tab.

What will Agios discuss during the call?

Agios will report its fourth quarter and full year 2025 financial results and business highlights.

Will there be a replay of the conference call?

Yes, a replay will be available on Agios' website approximately two hours after the event.

Last updated: Jan 26, 2026